Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

February 4, 2025

Study Completion Date

February 4, 2025

Conditions
HIV Infection
Interventions
OTHER

Analytical Treatment Interruption

"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."

Trial Locations (11)

Unknown

Gaborone CRS, Gaborone

Blantyre CRS, Blantyre

Malawi CRS, Lilongwe

CAPRISA eThekwini CRS, Durban

Vulindlela CRS, Durban

Kliptown Soweto CRS, Johannesburg

Ward 21 CRS, Johannesburg

Rustenburg CRS, Rustenburg

Milton Park CRS, Harare

Seke South CRS, Harare

Spilhaus CRS, Harare

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

HIV Prevention Trials Network

NETWORK

collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

HIV Vaccine Trials Network

NETWORK